Stifel Out Positive on Repligen (RGEN): 'current levels seem as though they will have proven to be good ones'
Tweet Send to a Friend
Stifel analyst Daniel Arias reiterated a Buy rating and $207.00 price target on Repligen (NASDAQ: RGEN).The analyst comments "Valuation. On ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
